• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of geriatric oncology >New treatment approaches in CLL: Challenges and opportunities in the elderly
【24h】

New treatment approaches in CLL: Challenges and opportunities in the elderly

机译：CLL的新治疗方法：老年人的挑战和机遇

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The majority of patients with chronic lymphocytic leukemia (CLL) are over 70 years old. These patients vary in their vulnerability toward treatment efforts. Heterogeneity in fitness of older patients with CLL is mainly determined by individual differences in physiological aging and pathological conditions such as comorbidities and geriatric syndromes. Various options exist to treat older patients with CLL outside and inside clinical trials. Among these are new treatment approaches, including chemoimmunotherapy with engineered CD20 antibodies (e.g., obinutuzumab), single agent therapy with Icinase inhibitors (e.g., ibrutinib, idelalisib), other targeted drug therapy (e.g., venetoclax, lenalidomide), and combinations of these novel compounds. Treatment recommendations for older patients take patient-related as well as disease-related risk factors into consideration. Emerging new treatment approaches in older patients offer novel opportunities, but also novel challenges which are discussed in this review. (C) 2016 Elsevier Ltd. All rights reserved.
机译：大多数慢性淋巴细胞性白血病（CLL）患者年龄超过70岁。这些患者对治疗努力的脆弱性各不相同。老年CLL患者适应性的异质性主要由生理衰老和病理状况（如合并症和老年综合症）的个体差异决定。在临床试验的内部和外部都有多种选择来治疗老年CLL患者。其中包括新的治疗方法，包括用工程CD20抗体进行化学免疫治疗（例如obinutuzumab），用Icinase抑制剂进行单药治疗（例如ibrutinib，idelalisib），其他靶向药物治疗（例如venetoclax，来那度胺）以及这些新型药物的组合化合物。针对老年患者的治疗建议考虑了患者相关以及疾病相关的危险因素。在老年患者中出现新的治疗方法不仅提供了新的机会，而且还提供了新的挑战，本文将对此进行讨论。 （C）2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号